Consistent discussion and improvement upon the standard practices of bioanalytical laboratories is critical to improving the work we do supporting innovative biologics development in the long-term. One of the rapidly advancing areas that is being regularly discussed in the industry is the evolution of ligand-binding assay (LBA) platforms. In this blog, I will summarize best practices and characteristics associated with LBA platforms as well as the features these platforms absolutely need to enable scientists to respond to industry pressures that drive demand for increasingly complex bioanalysis, condensed timelines, and continued…
In this Q&A session, Soubhik Banerjee, Director of Business Development at BioAgilytix Europe, talks about BioAgilytix’s approach to collaboration and the impact it has had on his work since joining the team a few months ago.
BioAgilytix Europe's Arno Kromminga fielded some excellent questions from attendees of his recent immunogenicity webinar. He recaps and expands upon several of those answers in our latest blog
A knowledgeable and committed CRO partner can make all the difference in a stalled out study, which in the right hands could go on to create a life-changing therapeutic innovation. We discuss what to look for in a “rescue project” partner.
Our team had the opportunity to both attend and present at a number of content-rich sessions during AAPS’ 2018 PharmSci 360 event. These conversations will have a direct impact on our own work moving forward, and we wanted to summarize and share a few of the key takeaways we found most interesting and valuable.
We’ve compiled some key questions to consider when selecting an outsourced partner for bioanalysis, so that you can set your large molecule study up for success from the very start.
What are the benefits of working with an expert team with an open-door policy? In this Q&A, Stuart Logan, BD Manager at BioAgilytix Europe, shares how his colleagues have supported his professional development.
Methods for the detection of drug-induced antibodies have become much more sensitive, but the question remains to be answered: are antibodies at this low concentration level clinically relevant?
With headquarters in the USA and Europe, effective team-wide communication is critical to our success. William Hunter, Director of BD & Global Key Accounts at BioAgilytix Europe, and Todd Lester, BPM at our USA HQ, discuss how they collaborate.
Biomarkers have the potential to inform the drug development process for both large and small molecule drugs. Learn more about our ability to carry out a wide variety of biomarker testing for both types of drugs.
